KBC Securities - Biotalys NV (BTLS) BIOTALYS: Putting puzzle pieces together BTLS BB

Report

KBC Securities

Guy Sips

BIOTALYS: Putting puzzle pieces together BTLS BB

Biotalys is a green AgTech, Agricultural Technology, company that develops biological crop and food protection products based on a proprietary antibody-based technology shaping the future of sustainable and safe food supply.
Over recent months, Biotalys signed -as part of its flexible, capital light business model- important long-term strategic partnerships with Biobest and Olon, putting puzzle pieces together.

12/01/2022 1 EN

Underlying

Biotalys NV

See profile

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Morning Note: AZE BB, BTLS BB, MITRA BB, Telecom BE

Azelis: Expansion into South America Biotalys: Partnership with Novozymes for Evoca Mithra: Additional details on private placement Telecom: Results mobile spectrum auction

June 21, 2022 June 21, 2022 1 EN

KBC Securities

KBCS New Horizon Conference Book AGFB BB, ARCAD NA, ASML NA, BAR BB, BTLS BB, DIE BB, EKOP BB, HYL BB, IBAB BB, MITRA BB, TWEKA NA

On Thursday 9 June, we organise our first New Horizon Conference in London. Following listed companies will be presented: • ASML • Agfa • Arcadis • Barco • Biotalys • D'Ieteren • Ebusco • Ekopak • Hyloris • IBA • Mithra • TKH We give a summary of our view on the companies we welcome, with key investment metrics that can serve as a guide during your meeting(s).

June 7, 2022 June 7, 2022 1 EN

KBC Securities

Morning Note: ASC BB, AZE BB, BTLS BB, COFB BB, EKOP BB

Ascencio: 1H21/22 Slightly ahead of expectations Azelis: Initiation - Formula for success, at a price Biotalys: BioProtection Award 2022 for Best Biofungicide Cofinimmo: Clearing out the old Offices Ekopak: Update on roll-out in France Various: Coverage update

May 25, 2022 May 25, 2022 1 EN

Merus Updated ASCO data confirm best-in-class potential in 1L HNSCC

Merus reported solid interim Ph2 data for ASCO 2025 with peto combo with Keytruda in 1L PD-L1+ r/m HNSCC, tracking nicely in line with last year's ASCO data. The updated dataset featured a 63% ORR (incl. 6 CRs), a mPFS of 9 months, and 12-month survival rate of 79%. Responses were observed across PD-L1 levels and HPV+ subgroups, and the treatment showed no new safety signals. The data support petosemtamab's potential to outperform Keytruda monotherapy and become the new gold standard in head and neck cancer. Ongoing Ph3 trials are progressing with interim topline data in one or both trials by...

May 23, 2025 May 23, 2025 1 EN

Jacob Mekhael

Jacob Mekhael

Inventiva Uneventful 1Q25 results, runway and pipeline timelines reiterated

Inventiva reported uneventful 1Q25 results, and confirmed its cash runway guidance, which is until the end of 3Q26. Timeline for the topline readout from the ongoing phase 3 trial of lanifibranor in MASH was also reiterated, with results expected in 2H26. With the funding overhang lifted, a fully recruited phase 3 trial in MASH, as well as competitive phase 2 data, we continue to see Inventiva as significantly undervalued and reiterate our € 7 TP and Buy rating.

May 23, 2025 May 23, 2025 1 EN

Guy Sips ... (+5)

Guy Sips
Hilde Van Boxstael
Thomas Vranken
Wim Hoste
Wim Lewi

Morning Notes : AKZA NA, SMAR BB, MRUS US

: AKZA NA, SMAR BB, MRUS US

May 23, 2025 May 23, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIOTALYS: Putting puzzle pieces together BTLS BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Note: AZE BB, BTLS BB, MITRA BB, Telecom BE

KBCS New Horizon Conference Book AGFB BB, ARCAD NA, ASML NA, BAR BB, BTLS BB, DIE BB, EKOP BB, HYL BB, IBAB BB, MITRA BB, TWEKA NA

Morning Note: ASC BB, AZE BB, BTLS BB, COFB BB, EKOP BB

Merus Updated ASCO data confirm best-in-class potential in 1L HNSCC

Inventiva Uneventful 1Q25 results, runway and pipeline timelines reiterated

Morning Notes : AKZA NA, SMAR BB, MRUS US

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe